640 related articles for article (PubMed ID: 21098324)
1. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.
Cho YJ; Tsherniak A; Tamayo P; Santagata S; Ligon A; Greulich H; Berhoukim R; Amani V; Goumnerova L; Eberhart CG; Lau CC; Olson JM; Gilbertson RJ; Gajjar A; Delattre O; Kool M; Ligon K; Meyerson M; Mesirov JP; Pomeroy SL
J Clin Oncol; 2011 Apr; 29(11):1424-30. PubMed ID: 21098324
[TBL] [Abstract][Full Text] [Related]
2. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.
Kool M; Koster J; Bunt J; Hasselt NE; Lakeman A; van Sluis P; Troost D; Meeteren NS; Caron HN; Cloos J; Mrsić A; Ylstra B; Grajkowska W; Hartmann W; Pietsch T; Ellison D; Clifford SC; Versteeg R
PLoS One; 2008 Aug; 3(8):e3088. PubMed ID: 18769486
[TBL] [Abstract][Full Text] [Related]
3. Medulloblastoma comprises four distinct molecular variants.
Northcott PA; Korshunov A; Witt H; Hielscher T; Eberhart CG; Mack S; Bouffet E; Clifford SC; Hawkins CE; French P; Rutka JT; Pfister S; Taylor MD
J Clin Oncol; 2011 Apr; 29(11):1408-14. PubMed ID: 20823417
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel homozygous deletion region at 6q23.1 in medulloblastomas using high-resolution array comparative genomic hybridization analysis.
Hui AB; Takano H; Lo KW; Kuo WL; Lam CN; Tong CY; Chang Q; Gray JW; Ng HK
Clin Cancer Res; 2005 Jul; 11(13):4707-16. PubMed ID: 16000565
[TBL] [Abstract][Full Text] [Related]
5. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma.
Mendrzyk F; Radlwimmer B; Joos S; Kokocinski F; Benner A; Stange DE; Neben K; Fiegler H; Carter NP; Reifenberger G; Korshunov A; Lichter P
J Clin Oncol; 2005 Dec; 23(34):8853-62. PubMed ID: 16314645
[TBL] [Abstract][Full Text] [Related]
6. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.
Ellison DW; Kocak M; Dalton J; Megahed H; Lusher ME; Ryan SL; Zhao W; Nicholson SL; Taylor RE; Bailey S; Clifford SC
J Clin Oncol; 2011 Apr; 29(11):1400-7. PubMed ID: 20921458
[TBL] [Abstract][Full Text] [Related]
7. Overexpressed TP73 induces apoptosis in medulloblastoma.
Castellino RC; De Bortoli M; Lin LL; Skapura DG; Rajan JA; Adesina AM; Perlaky L; Irwin MS; Kim JY
BMC Cancer; 2007 Jul; 7():127. PubMed ID: 17626635
[TBL] [Abstract][Full Text] [Related]
8. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia.
Eberhart CG; Kratz J; Wang Y; Summers K; Stearns D; Cohen K; Dang CV; Burger PC
J Neuropathol Exp Neurol; 2004 May; 63(5):441-9. PubMed ID: 15198123
[TBL] [Abstract][Full Text] [Related]
9. Dissecting the genomic complexity underlying medulloblastoma.
Jones DT; Jäger N; Kool M; Zichner T; Hutter B; Sultan M; Cho YJ; Pugh TJ; Hovestadt V; Stütz AM; Rausch T; Warnatz HJ; Ryzhova M; Bender S; Sturm D; Pleier S; Cin H; Pfaff E; Sieber L; Wittmann A; Remke M; Witt H; Hutter S; Tzaridis T; Weischenfeldt J; Raeder B; Avci M; Amstislavskiy V; Zapatka M; Weber UD; Wang Q; Lasitschka B; Bartholomae CC; Schmidt M; von Kalle C; Ast V; Lawerenz C; Eils J; Kabbe R; Benes V; van Sluis P; Koster J; Volckmann R; Shih D; Betts MJ; Russell RB; Coco S; Tonini GP; Schüller U; Hans V; Graf N; Kim YJ; Monoranu C; Roggendorf W; Unterberg A; Herold-Mende C; Milde T; Kulozik AE; von Deimling A; Witt O; Maass E; Rössler J; Ebinger M; Schuhmann MU; Frühwald MC; Hasselblatt M; Jabado N; Rutkowski S; von Bueren AO; Williamson D; Clifford SC; McCabe MG; Collins VP; Wolf S; Wiemann S; Lehrach H; Brors B; Scheurlen W; Felsberg J; Reifenberger G; Northcott PA; Taylor MD; Meyerson M; Pomeroy SL; Yaspo ML; Korbel JO; Korshunov A; Eils R; Pfister SM; Lichter P
Nature; 2012 Aug; 488(7409):100-5. PubMed ID: 22832583
[TBL] [Abstract][Full Text] [Related]
10. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations.
Thompson MC; Fuller C; Hogg TL; Dalton J; Finkelstein D; Lau CC; Chintagumpala M; Adesina A; Ashley DM; Kellie SJ; Taylor MD; Curran T; Gajjar A; Gilbertson RJ
J Clin Oncol; 2006 Apr; 24(12):1924-31. PubMed ID: 16567768
[TBL] [Abstract][Full Text] [Related]
11. Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features.
Leonard JR; Cai DX; Rivet DJ; Kaufman BA; Park TS; Levy BK; Perry A
J Neurosurg; 2001 Jul; 95(1):82-8. PubMed ID: 11453402
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of ARID1B, a tumor suppressor in the WNT subgroup medulloblastoma, activates multiple oncogenic signaling pathways.
Deogharkar A; Singh SV; Bharambe HS; Paul R; Moiyadi A; Goel A; Shetty P; Sridhar E; Gupta T; Jalali R; Goel N; Gadewal N; Muthukumar S; Shirsat NV
Hum Mol Genet; 2021 Aug; 30(18):1721-1733. PubMed ID: 33949667
[TBL] [Abstract][Full Text] [Related]
13. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
14. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors.
Northcott PA; Fernandez-L A; Hagan JP; Ellison DW; Grajkowska W; Gillespie Y; Grundy R; Van Meter T; Rutka JT; Croce CM; Kenney AM; Taylor MD
Cancer Res; 2009 Apr; 69(8):3249-55. PubMed ID: 19351822
[TBL] [Abstract][Full Text] [Related]
15. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
[TBL] [Abstract][Full Text] [Related]
16. Medulloblastoma in the age of molecular subgroups: a review.
Juraschka K; Taylor MD
J Neurosurg Pediatr; 2019 Oct; 24(4):353-363. PubMed ID: 31574483
[TBL] [Abstract][Full Text] [Related]
17. MiR-495 is a Predictive Biomarker that Downregulates GFI1 Expression in Medulloblastoma.
Wang C; Yun Z; Zhao T; Liu X; Ma X
Cell Physiol Biochem; 2015; 36(4):1430-9. PubMed ID: 26160036
[TBL] [Abstract][Full Text] [Related]
18. Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients.
Pan E; Pellarin M; Holmes E; Smirnov I; Misra A; Eberhart CG; Burger PC; Biegel JA; Feuerstein BG
Clin Cancer Res; 2005 Jul; 11(13):4733-40. PubMed ID: 16000568
[TBL] [Abstract][Full Text] [Related]
19. Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct.
Northcott PA; Hielscher T; Dubuc A; Mack S; Shih D; Remke M; Al-Halabi H; Albrecht S; Jabado N; Eberhart CG; Grajkowska W; Weiss WA; Clifford SC; Bouffet E; Rutka JT; Korshunov A; Pfister S; Taylor MD
Acta Neuropathol; 2011 Aug; 122(2):231-40. PubMed ID: 21681522
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic and molecular biological characterization of an adult medulloblastoma.
Holland H; Koschny R; Krupp W; Meixensberger J; Bauer M; Schober R; Kirsten H; Ganten TM; Ahnert P
Cancer Genet Cytogenet; 2007 Oct; 178(2):104-13. PubMed ID: 17954265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
